Navigation Links
Sequenom Announces Leadership Appointments
Date:12/11/2012

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Sequenom, Inc. (Nasdaq: SQNM) announced today the appointments of William Welch as the Company's President and Chief Operating Officer and Dirk van den Boom as the Company's Executive Vice President, Research & Development and Chief Technology Officer, both effective immediately.  Additionally, Ronald Lindsay has been named as the Company's Executive Vice President, Strategic Planning.  Harry F. Hixson, Jr. will continue to serve as Chairman and Chief Executive Officer.

Mr. Welch joined Sequenom in January 2011 as Senior Vice President, Diagnostics.  He has overseen the Company's commercial operations in connection with the October 2011 launch of its MaterniT21 PLUS laboratory-developed test.

"Bill's extensive industry experience and knowledge have been a significant asset to Sequenom over the last two years as we launched the MaterniT21 PLUS test," said Harry Hixson, Jr., Chairman and Chief Executive Officer.  "This promotion reflects his many contributions to the growth of our company and the board's confidence in his future leadership capacity."

Dr. van den Boom has served as Sequenom's Senior Vice President of research and development since August 2010 and previously served as the Company's vice president, research and development.  He joined Sequenom in 1998 at the company's Hamburg office, subsequently serving in various management roles of increasing responsibility within the R&D department.

"Dirk has demonstrated impressive professional and managerial growth over the past three years and we look forward to his contributions as he takes the helm of R&D leadership at Sequenom," said Ronald M Lindsay, Director and newly appointed EVP of Strategic Planning.  "We believe Dirk will successfully drive key strategic initiatives that will underpin the company's future
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Sequenom to Host Analyst Day on Monday, November 14, 2011
3. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
4. Sequenom Named to NASDAQ Global Select Market
5. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
6. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
7. Study In Prenatal Diagnosis Finds Sequenom CMMs MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets
8. Sequenom Announces Participation at the Jefferies Global Healthcare Conference
9. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
10. Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
11. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a ... development and manufacture of highly valued cardiac markers used in early detection of ... with protein chemistry has led to the development and commercialization of important cardiac ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... SAN DIEGO, Oct. 20 Cardium Therapeutics,(Amex: ... Inc., announced,today that it has received 510(k) clearance ... market the RapidBlue(TM) System, an endovascular,temperature modulation device. ... to manage and control patient body temperature.,This new ...
... joins Pierpoint International as Global VP of Recruitment Operations and Diversity ... ... -- Pierpoint International is pleased to announce the appointment of Robert ... most recently served as AVP of Staffing and Diversity for USAA, ...
... TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today announced ... a Phase I multiple dose clinical trial of NGX426, ... The trial is,designed to evaluate the safety, tolerability and ... days. NGX426 has been,safely administered to more than 150 ...
Cached Biology Technology:Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 2Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 3Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 4Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 5Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 6Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 7Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 8Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 9Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 10Robert Cantu Appointed Vice President of Pierpoint International 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 3TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 4
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... athletes looking to boost performance comes in the form of ... for its popularity is twofold says Scott Forbes, a doctoral ... for nitric oxide that is known to improve blood flow, ... to working muscles and assist with metabolic waste product removal. ...
... Bethesda, MD The Association for Molecular Pathology ... to exclusively license the subject matter of a cancer-related ... written remarks were submitted to NIH in response to ... entitled, "Prospective Grant of Exclusive License: The Development of ...
... of engineering principles to understand and treat medical conditions ... damage to the brain caused by a traumatic injury. ... presented in a special issue of Journal of ... Liebert, Inc. ( http://www.liebertpub.com ) The entire issue is ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3AMP opposes exclusive licensing of NIH proteomics patent 2Bioengineering yields new approaches for diagnosing and treating traumatic brain injury 2
... Camera hood with 5.6" TFT color screen, ... digimage system use digital camera with 8.0 mega ... space requirements and small budget. View image from ... it's specific feature. It is suitable to capture ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
Biology Products: